The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | RESPONSE-2 5-year follow-up update: ruxolitinib vs BAT in polycythemia vera without splenomegaly
Francesco Passamonti, MD, University of Insubria, Varese, Italy, gives an update on the RESPONSE-2 trial comparing ruxolitinib vs best available therapy (BAT) in patients with polycythemia vera (PV) without splenomegaly (NCT02038036). After a five-year follow-up, the study reported durable hematocrit control, as well as a significant decrease in the number of phlebotomies. In addition, there were no new safety signals. These data support the use of ruxolitinib as a second-line therapy in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
